Compare Toyota Motor Corp (TM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toyota Motor Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Toyota Motor Corp trades at $185.7 (market cap $217.38B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Toyota Motor Corp is the larger of the two by market cap, and Toyota Motor Corp pays a 3.37% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toyota Motor Corp for 116 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TM | VRTX | |
|---|---|---|
Market Cap | $217.38B | $127.55B |
Volume | 291,250 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $248.29 | $557.96 |
52-Week Low | $166.50 | $407.37 |
Typical Hold Time | 116 Days | 120 Days |
Enterprise Value | $410.96B | $121.68B |
Dividend Yield | 3.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Toyota Motor trades at $182.91, down 1.43% with bearish technical signals despite strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.38 and P/B of 0.93, while consistently beating earnings expectations in recent quarters. Recent news highlights Toyota's growing U.S. market share and electrification progress with 37.8% growth in EV sales. Cash flow trends show improvement with projected 2026 operating cash flow of $4.13T.
Toyota presents a value opportunity with solid profitability and market positioning, though near-term technical weakness and China sales challenges warrant caution. The company's hybrid technology leadership and North American expansion provide growth catalysts, while analyst consensus leans neutral with 62.5% hold ratings. Debt levels remain manageable at 41.29% debt-to-asset ratio.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
